Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc has demonstrated a strong upward trajectory with a 19% year-over-year growth in kidney surveillance volumes, reflecting the increasing demand for its testing services. The company has strategically expanded its sales force by approximately 50%, positioning itself for enhanced market penetration and revenue generation, with new representatives expected to ramp up within 6-9 months. Additionally, CareDx aims for an EBITDA margin target of 20% by 2027, along with a goal to increase its incremental cash target by over $100 million, indicating strong financial planning and growth potential.

Bears say

CareDx Inc faces significant concerns stemming from frequent changes in management over the past three years, which may impact the company's strategic direction and operational stability. Additionally, there are doubts regarding the company's ability to successfully commercialize new diagnostic solutions that are crucial for its growth, potentially hindering revenue generation. The company's uncertainty surrounding potential increases in Medicare reimbursement limits for kidney tests further complicates its revenue outlook, as increased testing limits may not materialize as hoped.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.